<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1531">
  <stage>Registered</stage>
  <submitdate>16/04/2007</submitdate>
  <approvaldate>16/04/2007</approvaldate>
  <nctid>NCT00462202</nctid>
  <trial_identification>
    <studytitle>Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong</studytitle>
    <scientifictitle>An Open Label Tolerability and Safety Study of KRX-101 (Sulodexide Gelcaps) for the Treatment of Type 2 Diabetic Nephropathic Patients With Persistent Microalbuminuria in Australia, New Zealand, and Hong Kong</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>KRX 101-302</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetic Nephropathy</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - sulodexide

Experimental: Sulodexide - Open label extension to original trial


Treatment: drugs: sulodexide


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Observed ACR level from the first visit to the end of study - Open label safety extension to assess long-term exposure to sulodexide (KRX-101) in patients with albumin and protein in their urine.</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  At least 18 years of age and has successfully completed Keryx Study 101-301.

          -  Diagnosis of DM2 based on ADA criteria.

          -  Continued stable seated systolic blood pressure &lt; 150 mmHg and diastolic blood
             pressure &lt; 90 mmHg.

          -  Provide written informed consent to participate in the study.

          -  If female and of childbearing potential, must continue to be willing to use adequate
             contraception, as determined by the investigator, for the duration of the study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Evidence of hepatic dysfunction including total bilirubin &gt; 2.0 mg/dL (34 micromol/L)
             or liver enzymes &gt; 3 times upper limit of normal.

          -  Unstable angina pectoris or New York Heart Association Class III or IV congestive
             heart failure.

          -  A history of any major medical condition, including but not limited to: aortic
             aneurysm; myocardial infarction, stroke, or other cardiovascular events in the past 3
             months; gastrointestinal bleeding in the past 3 months; HIV; and other medical
             conditions deemed serious by the investigator. Active Hepatitis B or C (currently
             active disease defined as an abnormal liver biopsy or persistent, elevated
             transaminases, SGOT, SGPT).

          -  Any risk of bleeding, including a history of bleeding diathesis and a platelet count &lt;
             100,000/mmÂ³.

          -  Active or metastatic cancer (note: superficial basal carcinoma of the skin is not an
             exclusion).

          -  Anticipated surgery within trial period.

          -  History of noncompliance to medical regimens in Keryx Study No.101-301.

          -  Participation in any experimental drug study in the past 60 days, except for
             KRX-101-301, prior to entry into the study, or plan to participate in any experimental
             drug study during the study period.

          -  Lactation, pregnancy, or an anticipated or planned pregnancy during the study period.

          -  Known allergy or intolerance to any heparin-like compounds.

          -  Patients with other specific renal diseases known to be the cause of nephropathy, and
             patients with other specific, clinically significant renal disease.

          -  Inability to give an informed consent or cooperate with the study personnel.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>200</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Monash Medical Center - Melbourne</hospital>
    <postcode>3168 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Keryx Biopharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Collaborative Study Group (CSG)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess the tolerability and safety of KRX-101 in treating
      persistent microalbuminuria in type 2 diabetic patients who are also being treated with
      stable, maximum tolerated doses of either ACE inhibitors or A2 receptor blockers.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00462202</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Robert Atkins, MD</name>
      <address>Monash Medical Centre</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>